Bassam Janji

ACB1801 enhances anti-PD-1 therapy efficacy in MSS CRC by reprogramming the TME through metabolic reprogramming and STAT1 signaling activation.

This study shows that targeting ACKR2 enhances anti-PD-1 immunotherapy efficacy in melanoma by improving the tumor microenvironment and immune cell infiltration.

This study identifies ALDH1A3 as a therapeutic target in aggressive breast cancers and develops ABD0171, a selective inhibitor showing antitumor and antimetastatic effects.